Post-effective amendment to a registration statement that is not immediately effective upon filing

NET LOSS PER SHARE (Tables)

v3.23.1
NET LOSS PER SHARE (Tables)
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Earnings Per Share [Abstract]    
Summary of Earnings per Shares, basic and diluted
Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted earnings per share (“EPS”) calculations for the periods ended:
Three Months Ended
March 31,
(In thousands, USD, except share and per share amounts) 2023 2022
Numerator:
Net loss $ (18,490) $ (11,572)
Denominator:    
Weighted average common shares outstanding    
Basic (in number) 76,524,735  74,040,261 
Diluted (in number) 76,524,735  74,040,261 
Net loss per unit    
Basic $ (0.24) $ (0.16)
Diluted $ (0.24) $ (0.16)
Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted earnings per share (“EPS”) calculations for the periods ended:
(In thousands, USD) December 31, 2022 December 31, 2021
Numerator:
Net loss attributable to the Company $ (106,200) $ (24,776)
Less cumulative earnings to preferred shareholder —  (22,822)
Add premium on preferred conversion to common shares —  4,074 
Net income (loss) attributable to common stockholders $ (106,200) $ (43,524)
Denominator:
Weighted average common shares and warrants outstanding
Basic (in number) 75,710,904  41,933,050 
Diluted (in number) 75,710,904  41,933,050 
Net loss per unit attributable to common stockholder
Basic $ (1.40) $ (1.04)
Diluted $ (1.40) $ (1.04)
Summary of Diluted Shares Outstanding
The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive:
Three Months Ended
(Number of shares) March 31,
2023 2022
Common stock issued under the Backstop Agreement 9,600,031  9,600,031 
Restricted stock grants with only service conditions 4,529,117  3,108,277 
Private placement warrants 272,779  272,779 
The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive:
(number of shares) December 31,
2022		 December 31,
2021
Restricted stock grants with only service conditions 3,552,416  — 
Common stock issued under the Backstop Agreement 9,600,031  9,600,031 
Private Placement Warrants 272,779  272,779 
Series C Convertible Preferred Stock —  2,566,186 
Stock Options —  432,500